MAIA Biotechnology expands promising Phase II trial, enrolling patients at prestigious Winship Cancer Institute, offering renewed hope for individuals unresponsive to existing therapies.
[City, State] – [Date] – In a significant development for non-small cell lung cancer (NSCLC) research, MAIA Biotechnology has announced the activation of a new US clinical site at the renowned Winship Cancer Institute of Emory University. This strategic expansion marks a crucial step in the ongoing Phase II THIO-101 expansion trial, which is now actively enrolling patients. The trial is investigating the potential of ateganosine, a novel telomere-targeting agent, in combination with cemiplimab, as a third-line therapy for NSCLC patients who have demonstrated resistance to both established chemotherapy regimens and current checkpoint inhibitor immunotherapies.
This marks Winship Cancer Institute as the third prominent US clinical site to join this multi-center study, underscoring the growing interest and potential of this innovative therapeutic strategy. The THIO-101 trial is specifically designed to address a critical unmet need in NSCLC treatment: the limited options available for patients whose cancer has progressed despite multiple lines of therapy.
The Promise of Ateganosine: A Novel Mechanism of Action
At the heart of this trial lies ateganosine (also known as THIO, 6-thio-dG, or 6-thio-2′-deoxyguanosine), a first-in-class investigational agent that targets telomeres. Telomeres are protective caps at the ends of chromosomes, crucial for maintaining genomic stability. In many cancers, including NSCLC, telomeres are abnormally maintained, often through the enzyme telomerase, which allows cancer cells to divide indefinitely. Ateganosine is designed to interfere with this process, aiming to disrupt telomere maintenance and ultimately induce cancer cell death.
"This expansion into Winship Cancer Institute is a pivotal moment for the THIO-101 trial," stated Matthew Failor, Director of Clinical Operations at MAIA Biotechnology. "Winship is Georgia’s only National Cancer Institute (NCI)-designated Comprehensive Cancer Center and is recognized at the forefront of cancer innovation and discovery nationwide. Their renowned thoracic oncology clinical research program, with a proven track record in clinical trial development and conduct, makes them an ideal partner. With their premier medical team and extensive body of research, this cancer center is exceptionally well-suited for our US Phase II trial of ateganosine."
The THIO-101 trial is an open-label, dose-finding, multi-center study. It is meticulously designed to evaluate the safety, tolerability, and efficacy of ateganosine administered in combination with cemiplimab. The primary endpoint for assessing efficacy in advanced NSCLC patients resistant to prior therapies is the overall response rate (ORR).
Addressing a Critical Unmet Need in Lung Cancer
Non-small cell lung cancer (NSCLC) remains the most common type of lung cancer, accounting for approximately 85% of all diagnoses. Despite significant advancements in treatment over the past decade, including the advent of targeted therapies and immune checkpoint inhibitors (ICIs), a substantial proportion of patients eventually develop resistance to these treatments. This resistance poses a major challenge, leaving many patients with limited subsequent therapeutic options and a poorer prognosis.
Traditional chemotherapy, while still a cornerstone of cancer treatment, often leads to significant side effects and can be ineffective in the long term for many NSCLC patients. Checkpoint inhibitors, which harness the power of the patient’s own immune system to fight cancer, have revolutionized treatment for some, but a significant number of patients do not respond to these therapies, or their cancer eventually becomes resistant.
It is within this challenging landscape that the THIO-101 trial and the potential of ateganosine offer a glimmer of hope. By targeting a fundamental aspect of cancer cell survival – telomere maintenance – ateganosine presents a distinct mechanism of action that could potentially overcome resistance to existing treatments. The combination with cemiplimab, an ICI that targets the PD-1 pathway, aims to create a synergistic effect, potentially enhancing the anti-tumor immune response while directly impacting cancer cell proliferation.
Chronology of the THIO-101 Trial: From Preclinical Promise to Clinical Expansion
The journey of ateganosine and the THIO-101 trial is a testament to rigorous scientific investigation and a phased approach to drug development.
- Early Preclinical Research: The development of ateganosine stemmed from extensive preclinical research exploring novel anti-cancer mechanisms. The understanding of telomere biology and its role in cancer cell immortality provided the foundation for designing agents that could specifically target this vulnerability.
- Phase I Studies: Initial Phase I studies would have focused on establishing the safety profile of ateganosine, determining the optimal dose and schedule, and identifying potential side effects in a broader patient population.
- Phase II THIO-101 (Initial Stages): The THIO-101 trial was initiated to evaluate ateganosine’s efficacy in NSCLC patients. Early parts of the study (Parts A and B) demonstrated promising early efficacy signals. Notably, some patients in these initial phases exceeded two years of survival, a significant achievement for individuals with advanced, treatment-resistant NSCLC. These encouraging results were instrumental in the decision to expand the trial, including the significant step of launching a US-based expansion.
- US Expansion and Site Activation: The activation of the Winship Cancer Institute as a new US site is a direct result of the positive early findings. This expansion allows for broader patient access to the trial within the United States, accelerating the accrual of data and increasing the statistical power of the study.
- Patient Enrollment at Winship: With the activation of the Winship site, patient enrollment is now officially open. This means eligible NSCLC patients being treated at Winship will have the opportunity to participate in this cutting-edge trial.
- Global Reach: The THIO-101 trial is a multi-center study with a global footprint. In July 2025, MAIA Biotechnology announced the dosing of the first subject in Taiwan in the expansion phase of this trial, highlighting the international effort to bring this potential new therapy to patients worldwide.
Supporting Data and Early Efficacy Signals
While specific detailed data from the early parts of the THIO-101 trial (Parts A and B) are not extensively detailed in the provided text, the statement that "Parts A and B demonstrated early efficacy, with some patients exceeding two years of survival" is a powerful indicator of the trial’s potential.
- Overall Response Rate (ORR): As the primary endpoint, ORR will measure the percentage of patients whose tumors shrink or disappear in response to the treatment. A higher ORR indicates greater efficacy.
- Survival Data: The mention of patients exceeding two years of survival is particularly significant in the context of advanced, treatment-resistant NSCLC. This metric suggests that the combination therapy may be offering a meaningful extension of life, a critical outcome for patients facing a dire prognosis.
- Safety and Tolerability: The trial’s assessment of ateganosine’s safety and tolerability is paramount. Establishing a manageable safety profile is crucial for any new drug, especially when considering combination therapies. The open-label nature of the trial allows for close monitoring of these aspects.
Official Responses and Expert Opinions
The strategic decision to expand the THIO-101 trial to a prominent institution like Winship Cancer Institute is met with enthusiasm from both the company and the participating institution.
Matthew Failor, Director of Clinical Operations at MAIA Biotechnology, expressed his confidence in the partnership: "Winship offers a renowned thoracic oncology clinical research program with a proven track record in clinical trial development and conduct. With its premier medical team and extensive body of research, this cancer center is well-suited for our US Phase II trial of ateganosine." This statement highlights MAIA Biotechnology’s commitment to conducting their trials at centers of excellence, ensuring the highest standards of patient care and data integrity.
Dr. Ticiana Leal, Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, is serving as the principal investigator for the trial at Winship. Her leadership in this trial underscores the institution’s dedication to advancing cancer research and offering novel treatment options to patients. While Dr. Leal’s direct quote is not provided, her role as principal investigator signifies her belief in the trial’s potential and her commitment to its successful execution.
Implications for the Future of Lung Cancer Treatment
The THIO-101 trial, and specifically the investigation of ateganosine in combination with cemiplimab, holds significant implications for the future of NSCLC treatment:
- New Hope for Treatment-Resistant Patients: The most immediate implication is the potential to offer a new therapeutic avenue for NSCLC patients who have exhausted current treatment options. This could translate to improved outcomes, extended survival, and enhanced quality of life for a population with limited alternatives.
- Validation of Telomere Targeting: If successful, this trial could validate telomere targeting as a viable and effective strategy in the fight against NSCLC and potentially other cancers. This could pave the way for the development of a new class of anti-cancer drugs.
- Synergistic Therapies: The combination approach highlights the growing trend towards developing synergistic therapies that combine different mechanisms of action to achieve greater efficacy than single agents. This could lead to more personalized and effective treatment regimens.
- Advancement of Precision Medicine: As research progresses, understanding which specific NSCLC subtypes or patient populations are most likely to benefit from ateganosine and cemiplimab will be crucial. This will contribute to the broader advancement of precision medicine in oncology.
- Accelerated Drug Development: The expansion of the trial into the US, coupled with the ongoing enrollment in Taiwan, demonstrates MAIA Biotechnology’s commitment to accelerating the development of ateganosine. Successful completion of Phase II could lead to expedited pathways for further clinical trials and potential regulatory approval.
The activation of the Winship Cancer Institute and the ongoing patient enrollment in the Phase II THIO-101 expansion trial represent a critical step forward in the quest for more effective treatments for non-small cell lung cancer. The innovative approach of targeting telomeres in combination with immunotherapy offers a promising new frontier, providing renewed hope for patients facing the challenges of treatment resistance. The scientific community and patients alike will be closely watching the progress of this important clinical trial.
About the Author
